Reducing Blockage Fails to Improve Access to the Bloodstream for Kidney Dialysis
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Reducing Blockage Fails to Improve Access to the Bloodstream for Kidney Dialysis

BETHESDA, Md -- May 23, 2008 -- Reducing early blockages in bloodstream access for kidney failure treatment does not increase the likelihood that the access will function adequately for long-term treatments, according to a study funded by the National Institutes of Health (NIH). Results were published May 14 in the Journal of the American Medical Association.

"Since most of the 470,000 Americans with kidney failure depend on hemodialysis for survival, there is a clear and compelling need to evaluate therapies that reduce or prevent access failure," said Elias A. Zerhouni, MD, Director, NIH. "These results tell us we need to keep looking for solutions."

The Dialysis Access Consortium (DAC), Bethesda, Maryland, found that only 12% of patients developed blood clots in the fistula when treated with the clot-preventing drug clopidogrel, compared with nearly 20% of patients treated with placebo. Nevertheless, about 60% of new fistulas in each group could not be used for long-term dialysis treatments.

The DAC studied nearly 900 patients at 9 US medical centres in academic and community practices in urban and rural settings. Participants received a new fistula and took the anti-platelet drug clopidogrel or a placebo tablet daily for 6 weeks to determine if the drug would maintain blood flow in fistulas and increase the number suitable for dialysis.

"Because vascular access is critical for delivering lifesaving care, we are already organising another multicentre study to look for other ways to improve fistulas," said co-author Catherine M. Meyers, MD, Program Officer, DAC, and Director, Inflammatory Renal Disease Program, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which funded the study.

The DAC Fistula Trial is the largest multicentre trial to look at preventing blood clots in new fistulas and the first to test whether prevention would allow more fistulas to be useable for dialysis.

SOURCE: US National Institutes of Health

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities